Document:

Ohr Pharmaceutical, Inc. 10-K
Exhibit 10.2(d)

 

OHR PHARMACEUTICAL, Inc. 

2014 STOCK INCENTIVE PLAN

Restricted Stock Agreement

No. of shares subject to

Restricted Stock Agreement: 120,000

THIS RESTRICTED STOCK AGREEMENT
(this “Agreement”) dated as of the 11th day of  December, 2015, between Ohr Pharmaceutical, Inc., a Delaware
corporation (the “Company”), and Irach B. Taraporewala (the “Participant”), is made pursuant and
subject to the provisions of the Company’s 2014 Stock Incentive Plan (the “Plan”), a copy of which is
attached hereto. All terms used herein that are defined in the Plan have the same meaning given them in the Plan.

1.

Grant of Shares. Pursuant to the
Plan, the Company, on December 11, 2015 (the “Date of Grant”), granted to the Participant, subject to the terms and
conditions of the Plan and subject further to the terms and conditions set forth herein, 120,000 shares (the “Shares”)
of the common stock, par value $0.0001 per share, of the Company. The Shares shall be nontransferable and forfeitable until the
time they vest and become nonforfeitable as described herein. The Shares will vest and become nonforfeitable as hereinafter provided.

2.

Terms and Conditions. The Shares
are subject to the following terms and conditions:

(a)

Vesting of Shares.

(i)

In General. Subject to earlier vesting
or forfeiture as provided below, the Participant’s interest in 100% of the Shares shall be vested on the following dates,
provided that the Participant has been continuously providing services to the Company from the Date of Grant until each such time
pursuant to that certain Consulting Agreement, dated as of the date hereof (the “Consulting Agreement”), between the
Company and the Participant:

 

	
         

        Date
	
         

        Percentage of Shares Vested

         

	July 16, 2016	25%
	January 16, 2017	25%
	July 16, 2017	25%
	January 16, 2018	25%

 

(ii)

Sale of the Company. Notwithstanding
the foregoing, in the event a Sale of the Company occurs and no provision is made for the continuance, assumption or substitution
of the Shares by the Company or its successor in connection with a Sale of the Company, then, the Shares shall fully vest and become
nonforfeitable as of the date of the Sale of the Company provided the Participant has been continuously providing services to the
Company or any Affiliate pursuant to the Consulting Agreement from the Date of Grant until such time.

(iii)

Death or Disability. Notwithstanding
the foregoing, the Shares shall fully vest and become nonforfeitable, to the extent not then previously vested, in the event the
Participant’s employment or service with the Company and its Affiliates is terminated as a result of the Participant’s
death or Disability. The Committee, in its sole discretion, shall determine whether the Participant has a Disability for purposes
of this Agreement.

 

    	 

    	 

    

 

(b)

Transferability. The Shares are
nontransferable while such Shares remain forfeitable No right or interest of the Participant in the Shares shall be liable for,
or subject to, any lien, obligation or liability of the Participant or any transferee.

3.

Forfeiture of the Shares.

(a)

The Shares will become vested and nonforfeitable,
if at all, no later than January 16, 2018. The Shares that are not vested and nonforfeitable by such time will be forfeited automatically
at the close of business on that date or, if earlier, at the time the Shares may no longer become vested and nonforfeitable under
any circumstances.

(b)

Shares that are not vested and nonforfeitable
pursuant to Section 2(a) as of the date of termination of the Participant’s service with the Company and its Affiliates will
be forfeited automatically at the close of business on that date (or, if earlier, in connection with the termination of the Participant’s
service with the Company and its Affiliates for Cause).

(c)

In no event may the Shares become vested
and nonforfeitable, in whole or in part, after forfeiture pursuant to Sections 3(a) or (b) above.

4.

Agreement to Terms of the Plan and Agreement.
The Participant has received a copy of the Plan, has read and understands the terms of the Plan and this Agreement, and agrees
to be bound by their terms and conditions.

5.

Withholding of Taxes. The Company’s
obligation to deliver the Shares upon vesting is subject to the Participant’s satisfaction of any applicable federal, state
and local income and employment tax and withholding requirements in a manner and form satisfactory to the Company. The Company,
to the extent applicable law permits, may allow the Participant to pay such withholding amounts (i) by surrendering (actually or
by attestation) shares of Common Stock that the Participant already owns (but only for the minimum required withholding), (ii)
by a cashless exercise through a broker, (iii) by means of a “net exercise” procedure or (iv) by such other medium
of payment as the Company in its discretion shall authorize.

6.

Tax Consequences. The Participant
acknowledges (i) that there may be adverse tax consequences upon acquisition, vesting and/ or disposition of the Shares and (ii)
that Participant should consult a tax adviser prior to such acquisition or disposition. The Participant is solely responsible for
determining the tax consequences of the Shares and for satisfying the Participant’s tax obligations with respect to the Shares
(including, but not limited to, any income or excise tax as resulting from the application of Code Section 83 or 409A), and the
Company shall not be liable if this Award is subject to Code Section 409A.

7.

Fractional Shares. Fractional shares
shall not be issuable hereunder, and when any provision hereof may entitle the Participant to a fractional share such fractional
share shall be disregarded.

8.

Change in Capital Structure. The
terms of this Agreement shall be adjusted in accordance with the terms and conditions of the Plan as the Committee determines is
equitably required in the event the Company effects one or more stock dividends, stock splits, subdivisions or consolidations of
shares or other similar changes in capitalization.

9.

Notice. Any notice or other communication
given pursuant to this Agreement, or in any way with respect to this Agreement, shall be in writing and shall be personally delivered
or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the following addresses:

	 	If to the Company:	Ohr Pharmaceutical, Inc. 
	 	 	800 Third Ave, 11th Floor
	 	 	New York, NY 10022
	 	 	Attention:  Chief Financial Officer
	 	 	 
	 	If to the Participant:	Irach B. Taraporewala  
	 	 	24 Carhart Avenue
	 	 	White Plains, NY 10605

 

    	 

    	 

    

 

10.

Shareholder Rights. While the Shares
may be forfeited and are nontransferable, a Participant will have all rights of a stockholder with respect to the Shares, including
the right to receive dividends and vote the shares; provided, however, that during such period (a) a Participant may not sell,
transfer, pledge, exchange, hypothecate or otherwise dispose of the Shares, (b) the Company shall retain custody of any certificates
evidencing the Shares and (c) the Participant will deliver to the Company a stock power, endorsed in blank, with respect to this
Agreement. In lieu of retaining custody of the certificates evidencing Shares granted pursuant to this Agreement, the shares of
Common Stock granted pursuant to this Agreement may, in the Company’s discretion, be held in escrow by the Company or recorded
as outstanding by notation on the stock records of the Company until the Participant’s interest in such Shares vest.

11.

No Right to Continued Employment or Service.
Neither the Plan, the granting of the Shares nor any other action taken pursuant to the Plan or this Agreement constitutes or is
evidence of any agreement or understanding, expressed or implied, that the Company or any Affiliate shall retain the Participant
as an employee or other service provider for any period of time or at any particular rate of compensation.

12.

Binding Effect. Subject to the limitations
stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and
personal representatives of the Participant and the successors of the Company.

13.

Conflicts. In the event of any conflict
between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall govern. All references
herein to the Plan shall mean the Plan as in effect on the date hereof.

14.

Counterparts. This Agreement may
be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute
one in the same instrument.

15.

Miscellaneous. The parties agree
to execute such further instruments and take such further actions as may be necessary to carry out the intent of the Plan and this
Agreement. This Agreement and the Plan shall constitute the entire agreement of the parties with respect to the subject matter
hereof.

16.

Section 409A. Notwithstanding any
of the provisions of this Agreement, it is intended that this Agreement be exempt from Section 409A of the Code. Notwithstanding
the preceding, neither the Company nor any Affiliate shall be liable to the Participant or any other person if the Internal Revenue
Service or any court or other authority have any jurisdiction over such matter determines for any reason that this Agreement is
subject to taxes, penalties or interest as a result of failing to be exempt from, or comply with, Section 409A of the Code.

17.

Section 83(b) Election. If
the Participant makes an election under Section 83(b) of the Code to be taxed with respect to the Award of Restricted Stock as
of the date of transfer of the Restricted Stock rather than as of the date or dates upon which the Participant would otherwise
be taxable under Section 83(a) of the Code, the Participant shall deliver a copy of such election to the Company at or prior to
the time of filing such election with the Internal Revenue Service. Neither the Company nor any Affiliate shall have any liability
or responsibility relating to or arising out of the filing or not filing of any such election or any defects in its construction.

18.

Governing Law. This Agreement shall
be governed by the laws of the State of New York, except to the extent federal law applies.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the Company has caused
this Agreement to be signed by a duly authorized officer, and the Participant has affixed his signature hereto.

 

	 	COMPANY:
	 	 
	 	OHR PHARMACEUTICAL, INC. 
	 	 
	 	 
	 	By:	/s/ Jason S. Slakter
	 	Name:	Jason S. Slakter, MD
	 	Title:	CEO 
	 	 
	 	 
	 	PARTICIPANT:
	 	 
	 	/s/ Irach B. Taraporewala 
	 	Irach B. TaraporewalaOhr Pharmaceutical, Inc. 10-K

Exhibit
10.2(e)

 

Lock-Up
Agreement

 

 

December
11, 2015

 

Ohr Pharmaceutical, Inc.

800 Third Ave, 11th Floor

New York, NY 10022

 

Ladies and Gentlemen:

As an inducement to Ohr Pharmaceutical, Inc.
(the “Company”) to execute a consulting agreement with Irach B. Taraporewala, the undersigned hereby
agrees that without, in each case, the prior written consent of the Company during the period specified in the second succeeding
paragraph (the “Lock-Up Period”), the undersigned will not: (1) offer, pledge, announce the intention
to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of common
stock, par value $0.0001 per share (the “Common Stock”), of the Company or any securities convertible
into, exercisable or exchangeable for or that represent the right to receive Common Stock (including without limitation, Common
Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities
and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter
acquired (the “Undersigned’s Securities”); (2) enter into any swap or other agreement that transfers,
in whole or in part, any of the economic consequences of ownership of the Undersigned’s Securities, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise;
(3) make any demand for or exercise any right with respect to, the registration of any Common Stock or any security convertible
into or exercisable or exchangeable for Common Stock; or (4) publicly disclose the intention to do any of the foregoing.

 

The undersigned agrees
that the foregoing restrictions preclude the undersigned from engaging in any hedging or other transaction which is designed to
or which reasonably could be expected to lead to or result in a sale or disposition of the Undersigned’s Securities even
if such Securities would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would
include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or
call option) with respect to any of the Undersigned’s Securities or with respect to any security that includes, relates to,
or derives any significant part of its value from such Securities.

 

The Lock-Up Period
will commence on the date of this Agreement and continue and include the date 180 days after the date hereof.

Notwithstanding
the foregoing, the undersigned may transfer (1) the Undersigned’s Securities (i) as a bona fide gift or gifts; (ii)
to an immediate family member of the undersigned or any trust for the direct or indirect benefit of the undersigned or the immediate
family of the undersigned or to any corporation, partnership, limited liability company, or other business entity all of the equity
holders of which consist of the undersigned and/or one or more members of such undersigned’s immediate family; and (iii)
transfers by testate succession or intestate succession; provided, in each case, that (x) such transfer shall not involve
a disposition for value, and (y) the transferee agrees in writing with the Company to be bound by the terms of this Lock-Up Agreement
that are applicable to the transferor, to the extent and for the duration that such terms remain in effect at the time of the transfer.
For purposes of this Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, nor
more remote than first cousin.

In addition, the
foregoing restrictions shall not apply to the exercise of stock options granted pursuant to the Company’s equity incentive
plans; provided that it shall apply to any of the Undersigned’s Securities issued upon such exercise.

    	 

    	 

    

 

In furtherance of
the foregoing, the Company and its transfer agent and registrar are hereby authorized to decline to make any transfer of Common
Stock if such transfer would constitute a violation or breach of this Agreement.

The undersigned
hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that upon request,
the undersigned will execute and additional documents necessary to ensure the validity or enforcement of this Agreement. All authority
herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns,
heirs or personal representatives of the undersigned.

This Agreement shall be
governed by, and construed in accordance with, the laws of the State of New York.

 

	 	Very truly yours,
	 	 
	 	 
	 	IRACH B. TARAPOREWALA
	 	Printed Name of Holder
	 	 
	 	/s/	IRACH B. TARAPOREWALA
	 	 	Signature
	 	 

 

ACCEPTED AND ACKNOWLEDGED

 

 

OHR PHARMACEUTICAL, INC.

 

 

	By:	/s/ Jason S. Slakter	 
	 	Name: Jason S. Slakter, MD	 
	 	Title: CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]